David Horne, MD, MPH Division of Pulmonary and Critical Care Harborview Medical Center
description
Transcript of David Horne, MD, MPH Division of Pulmonary and Critical Care Harborview Medical Center
“You want me to take how many months of medication?”:
Advising your patient on risks vs. benefits of LTBI treatment
David Horne, MD, MPHDivision of Pulmonary and Critical Care
Harborview Medical CenterUniversity of Washington
Outline
• LTBI: Definition, Guideline History
• Risks: Progression to Active TB
• Risks: Treatment
• Cost vs. Benefit
• Discussing with your patient
• Caveat – examples use TST & isoniazid
What is Latent TB Infection?• Evidence of prior exposure to Mtb, based on interrogation of T
cells, without clinical, radiographic or microbiologic evidence of active disease– “latency” should not imply dormancy of Mtb without metabolic activity
TB historically 2-state condition: active TB or latent infectionSpectrum
TB: Outcomes after Exposure
• Dogma Lifetime risk of reactivation TB: 5-10%
• Patient – May be substantial over- or under-estimate of risk
Small NEJM 2001
LTBI Screening & Treatment Balance
• 70% of TB cases in U.S. due to reactivation
• LTBI treatment is effective
• Only 10% of individuals with positive LTBI test will progress to active TB
• Adverse effects related to treatments
• Poor completion rates
LTBI Screening Recommendations – A History
• Isoniazid - introduced in 1952 for treatment of active TB – In 1955, use expanded to include treatment of LTBI – Campaign for widespread prophylaxis instituted (genl popln screening)
• Early 1970s, liver injury & deaths due to isoniazid hepatotoxicity– 1974, ATS recommended restricting prophylaxis to < 35 years of age
unless increased risk for activation– Ensuing years, further decrease in INH use among young individuals
• 2000 Guidelines -“Targeted Tuberculin Testing” – INH-related morbidity lower than believed– Focus on testing/treatment of individuals at high risk of progression to
active TB
LTBI recommendations
• “Targeted tuberculin testing for LTBI identifies persons at high risk for developing TB who would benefit by treatment of LTBI, if detected.” – 2000 ATS Guidelines, “Targeted Tuberculin
Testing and Treatment of LTBI”
Targeted Testing (2000 Guidelines)
Recent Infection with M. tuberculosis
•Close contacts
•Recent immigrants from areas with high TB rates (< 5 years)
•Known converters
•Children younger than 5 years
•Homeless, IVDU, institutional setting exposures
Increased Risk for Progression
•HIV infection
•CXR suggestive of old TB (fibrotic)
•Medical conditions: diabetes, silicosis, dialysis, cancer, underweight
•Medically immunosuppressed
Targeted Testing – Broad Identification
• 22 y/o Filipino woman, immigrated 3 years ago: TST 15mm, CXR normal
• Same person, but 42 years of age & immigrated 3 years prior
• Same person, but 72 years of age & immigrated 3 years prior
Updated Risk Estimates for Active TB
Risk of TB: Comparing Estimates
RR Estimates, ATS Guidelines
10-25
2-4 30
2-5
Risk Active TB: Age
Horsburgh, NEJM 2004 350
Risk of Active TB
Risk of Active TB: Immigration
• Targeted Testing includes recent (< 5 years) immigrants from areas with high TB rates– New arrivals from high-incidence countries hypothesized to
arrive with high-risk “early latency” because of ongoing exposure
– High TB rates immediately after arrival assumed to indicate that reactivation risk declines with time in US
• U.S. TB cases –63% among foreign born (2012)
U.S. TB Cases: Different Trends by Birth
TB Case Rates Remain Elevated in Foreign Born for Years after Immigration
Cain JAMA 2008
Changes in Reactivation Risk Among Immigrants
• To address marked difference between 1st year and subsequent years following immigration, Walter et al looked at immigration from Philippines
• Separated out those who had abnormal immigration CXR and developed TB in 1st year (presumed active & inactive TB)
• Among those with normal CXRs: There was no decline in TB reactivation over 9-year period (32/100,000)
Walter AJRCCM 2014
Durable Reactivation Risk Differs by Region of Origin
Cain AJRCCM 2007
PHSKC Annual Report on TB, 2010
Seattle-King County Experience
Risk of Active TB - Summary
• Major Risk Factors include: – Age– HIV– CXR: upper lobe fibronodular disease• Moderate Risk:– Recent Conversion• Among immigrants risk varies by region of origin
and may persist
Treatment Risks• Of INH adverse effects, drug-induced liver injury (DILI) most feared• Significant transaminase elevation: 0.1-0.6%
– RFs: age, EtOH, ethnicity– USPHS study from 1970’s still quoted: 20 - 34 years 0.3%, 35-49 = 1.2%,
50 – 64 = 2.3%, >65 years = 4.6%– Seattle study: 0.28% of >65 years
• 2004-08:17 severe adverse events associated with INH– 5 died, 5 liver txp…estimated 291,000-433,000 treated annually
• Other LTBI regimens likely safer than INH
Cost-Benefit – the Societal Perspective
• Older studies have supported screening and treatment of LTBI as cost-effective for all risk groups (e.g. Rose Arch Int Med 2000)
• Recent study using revised estimates of LTBI progression, completion rates of LTBI identified cost effectiveness for certain risk groups (Linas AJRCCM 2011)
Cost-Benefit – the Societal Perspective
Assessing your patient’s risk…
Individual Risk Stratification: Online TST/IGRA Interpreter www.tstin3d.com
TB – Risk Estimates tstin3d.com
• 22 y/o Filipino woman, immigrated 3 years ago: TST 15mm, CXR normal5.8% lifetime risk
• 42 y/o Filipino woman, immigrated 3 years ago: TST 15mm, CXR normal3.8% lifetime risk
• 42 y/o Filipino woman, immigrated 3 years ago : TST 15mm, DM (Hgb A1c 7.9) 10.6% lifetime risk
• 42 y/o Filipino woman, immigrated 3 years ago : TST 15mm, CXR shows stable RUL fibronodular changes 47.6% lifetime risk
• 73 y/o Filipino woman, immigrated 3 years ago : TST 15mm, CXR normal 0.7% lifetime risk
Risk Estimates - tstin3d.com
• May overestimate individual risk of TB progression– Assumes baseline annual risk of TB = 0.1% in healthy persons– If patient is recent close contact, then risk of TB is 5% for the
first 2 years and 0.1% thereafter– Horsburgh differences
• Same baseline risk, lower risks following new conversion by age group
• Lower risks for progression in co-existing conditions
• May overestimate INH DILI risk
Shared Decision Making – Risk Stratification & Advising Your Patient
• At what level of risk for TB progression should you recommend LTBI Treatment?– No guideline recommendations
• Some experts use cut-offs of 3% risk or 5% risk• Based on USPHS study estimated risk of age-related INH
toxicity (50 – 64 = 2.3%, >65 years = 4.6 percent)• Remember: Seattle study, 0.28% of >65 years
Shared Decision Making
• Firm cut-off will not be appropriate for all situations– Individual “costs” involve more than DILI
• Discuss with patient using available tools
• Patients need to be motivated to actually complete treatment – Completion rates < 50% in many series
In Summary…
• Risk for progression to active TB varies by patient factors
• Age of patient important in calculating life-time risk
• Duration of risk following immigration likely longer than previously stated; region of origin may impact risk
In Summary…• Better tools are available for risk assessment and may aid
clinicians and patients in considering LTBI treatment
• To treat or not to treat? Have a discussion
• Alternative Regimens are increasingly popular – improved completion rates
• LTBI guidelines overdue for update
Questions/Comments?